RxDoctor Payments Data

Mark Pane

Physician Assistant · Winston Salem, NCNPI 1801845722

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $96,892 of the $123,198 with a category attached, or 78.6%. AbbVie accounts for 65.1% of it on its own, with 59 other manufacturers making up the rest. Reporting peaked in 2023 at $43,163 and has fallen 98.2% since, to $768 in 2025. Among physician assistant clinicians in NC with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$123,198in general payments, 2019–2025

Across 1,737 payments — averaging $70.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$80K
  • Biohaven Pharmaceuticals, Inc.$13K
  • Biogen$12K
  • Biohaven Pharmaceutical Holding Company Ltd.$2K
  • Teva Pharmaceuticals USA, Inc.$1K
  • UCB, Inc.$1K
  • plus $13K from 54 others

What the payments were for

  • Consulting fees$3,1133%
  • Speaking & faculty fees$96,89279%
  • Travel & lodging$1,5711%
  • Food & beverage$21,33217%
  • Education$2900%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)328$80,224
Biohaven Pharmaceuticals, Inc.65$12,512
Biogen65$12,021
Biohaven Pharmaceutical Holding Company Ltd.46$2,413
Teva Pharmaceuticals USA, Inc.140$1,349
UCB, Inc.78$1,336
Mallinckrodt Hospital Products Inc.95$1,326
Acadia Pharmaceuticals Inc113$997
Novartis61$832
Bristol Myers Squibb98$814
SK Life Science, Inc.53$732
MDD US Operations, LLC66$708
Neurocrine Biosciences, Inc.53$615
EMD Serono, Inc.37$598
Pfizer42$496
ANI Pharmaceuticals, Inc.33$443
Amneal Pharmaceuticals LLC29$373
Supernus Pharmaceuticals, Inc.41$356
Sanofi14$355
Sunovion Pharmaceuticals Inc.22$352
Johnson & Johnson12$251
AstraZeneca(2 entities)14$242
Merz Pharmaceuticals, LLC11$239
Amgen17$234
Eisai Inc.11$211
Collegium Pharmaceutical, Inc.15$210
Takeda Pharmaceuticals U.S.A., Inc.8$205
Greenwich Biosciences, Inc.12$203
TG Therapeutics, Inc.11$203
Jazz Pharmaceuticals Inc.8$192
Lilly USA, LLC11$168
Banner Life Sciences, LLC7$151
Neurelis, Inc.7$146
Adamas Pharmaceuticals, Inc.12$136
Acorda Therapeutics, Inc9$135
Axsome Therapeutics, Inc.6$129
Avion Pharmaceuticals7$113
Argenx US, Inc.5$106
E.r. Squibb & Sons, L.L.C.4$87
Arbor Pharmaceuticals, Inc.6$86
Impel Pharmaceuticals Inc.6$86
Corium, LLC7$80
Lundbeck LLC5$70
GRT US Holding, Inc.4$69
Ipsen Biopharmaceuticals, Inc4$59
Kyowa Kirin, Inc.4$58
Genentech USA, Inc.4$45
Boston Scientific1$44
Grifols USA, LLC2$37
Merck3$36
Abbott2$35
Avanir Pharmaceuticals, Inc.2$34
Otsuka America Pharmaceutical, Inc.2$31
Aquestive Therapeutics, Inc.2$31
CSL Behring2$31
Upsher-smith Laboratories LLC2$30
Sumitomo Pharma America, Inc.7$25
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC1$24
Azurity Pharmaceuticals, Inc.1$21
Idorsia Pharmaceuticals US Inc1$17

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$123,198 in reported general payments places this provider in the 95th percentile of 7,441 physician assistant providers in North Carolina.

See all physician assistant providers in North Carolina

Medicare billing

Part B allowed, 2024
$60,537
Medicare patients
77
Services billed
3,479

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Kesimpta PenOfatumumab26$237,049
Nurtec OdtRimegepant Sulfate49$79,724
UbrelvyUbrogepant43$67,445
QuliptaAtogepant54$66,311
Dalfampridine ErDalfampridine22$8,310
Topiramate ErTopiramate12$8,308
Rivastigmine31$4,915
Gabapentin150$4,179
Pregabalin86$2,404
Buprenorphine15$2,333
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen67$2,096
Lamotrigine129$1,992
Lidocaine-PrilocaineLidocaine/Prilocaine13$1,964
Divalproex Sodium ErDivalproex Sodium18$1,517
Acetazolamide19$1,403

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieUbrelvy, Qulipta$80,224$133,75697 claims
PfizerNurtec Odt$496$79,72449 claims
Upsher-smith Laboratories LLCTopiramate$30$59581 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 7,441 physician assistant providers in North Carolina.

Other physician assistant in Winston Salem

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →